P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.
Tools for Startups
Explore this list of useful tools for startups to help you manage any task in your company: Data, Accounting, Marketing, Operations, etc.
Exclusive Access to New Technologies
Join our newsletter and find the invention that is a perfect match for your company. We will notify you of new technologies before publishing them on the website.
An antibody composition to treat drug use, drug addiction, and effects of drug use
The present disclosure provides compositions and methods for selectively killing cancer cells, wherein the composition comprises a compound of Formula (I). The selective killing of cancer cells occurs with an improved potency and safety profile compared to similar compounds. In particular, the compositions and methods of the invention show reduced platelet toxicity and retained or improved toxicity in cancer cells.
BioVentures was established as a formal outgrowth of the University of Arkansas for Medical Sciences‘ (UAMS) interest in promoting a biomedical technology industry for Arkansas and translating its research into products that benefit human health.
UAMS established BioVentures to maximize global, industrial interaction with the University of Arkansas faculty, as well as to facilitate technology transfer, the development of startup companies that are based on technology developed at UAMS, and contributions to Arkansas’ economic development.
BioVentures links the research minds at UAMS to global markets in order to advance Arkansas’ scientific and economic development.